Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Dosage of Tang Ning Tongluo Capsule for Type II Diabetes
NCT02161276Phase 2Completed
- Sponsor
- Guizhou Bailing Group Pharmaceutical Co., Ltd.
- Start
- Apr 2014
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Tangning Tongluo Capsule in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Guizhou Bailing Group Pharmaceutical Co., Ltd. Primary endpoints: Glycosylated Hemoglobin A1C at 8 weeks and Blood Glucose Level at 8 weeks. Started Apr 2014; status: completed.
02
Drugs
Tangning Tongluo Capsule
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02161276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02161276.